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1607-551X/Copyright ª 2015, KaohsiuAbstract The purpose of this study was to investigate the combined effects of Ginkgo biloba
extract and phenytoin (PHT) sodium as a dose regimen simulating the clinical treatment of pa-
tients with epilepsy, on P-glycoprotein (P-GP) overexpression in a pentylenetetrazole-kindled
mouse model of epilepsy. Epilepsy was induced by intraperitoneal administration of pentyle-
netetrazole (40 mg/kg) for 7 days followed by intragastric administration of PHT (40 mg/kg)
for 14 days. Thirty mice that developed seizures were randomly divided into three groups
and administered PHT as well as the following treatments: saline (negative control); verapamil
(20 mg/kg, positive control); and G. biloba (30 mg/kg). Seizure severity was recorded 30 mi-
nutes after treatment on Day 4 of drug administration, after which the mice were euthanized,
and their brains isolated. Western blots and immunohistochemistry were performed to analyze
the expression of P-GP and caspase-3, respectively, in the brain tissue. High-performance
liquid chromatography was used to measure the concentrations of PHT in the brains of the
treated mice. After 4 consecutive days of treatment, the seizure severity in the mice in the
G. biloba extract group was more significantly reduced than the seizure severity in the saline
control group, and a significant difference was observed between the G. biloba extract and
verapamil control groups (p < 0.05). P-GP expression in the brain more significantly decreased
in the mice treated with G. biloba extract and verapamil than it did in the saline-treated con-
trol group (p < 0.05). Compared with the saline-treated control group, the mice treated with
G. biloba extract and verapamil showed significantly increased brain PHT concentrations
(p < 0.05). Furthermore, caspase-3 expression in the brain tissue of the G. biloba extract groupeclare no conflicts of interest.
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P-glycoprotein overexpression 399was significantly lower than that in the vehicle control group (p < 0.05); this finding demon-
strated the neuroprotective effects of G. biloba. Therefore, this study showed that treatment
with G. biloba extract in combination with PHT prevented the upregulation of P-GP expression
in mice. Moreover, G. biloba extract decreased seizure severity in pentylenetetrazole-kindled/
PHT-treated mice through a mechanism that might be related to the reduction of P-GP expres-
sion in the brain.
Copyright ª 2015, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Epilepsy is a common neurological disorder. In about 30% of
patients with epilepsy, the disorder is not controlled
effectively by antiepileptic drug administration [1] and is
known as refractory epilepsy. The mechanisms of drug
resistance in the treatment of epilepsy remain a critical
focus of intense academic research, which has indicated
that several diverse cellular mechanisms are involved in the
process [2]. The analysis of brain tissue from patients with
epilepsy revealed the absence of nerve and radial glial
cells. A recent study has shown that drug-resistant proteins
were markedly overexpressed in the brains of patients with
epilepsy [2]. This protein overexpression may be respon-
sible for drug resistance in patients with refractory epi-
lepsy, because such proteins may increase drug expulsion
from the brain. These results indicated that the over-
expression of P-glycoprotein (P-GP) might mediate resis-
tance to some antiepileptic drugs. Therefore, the inhibition
of P-GP may inhibit resistance to common antiepileptic
drugs.
It has been reported that calcium ion pathways may play
an important role in P-GP expression [3]. Our previous study
demonstrated that flunarizine, a calcium ion antagonist,
effectively downregulated P-GP expression [4]. The rela-
tionship between P-GP expression and antiepileptic drug
concentrations in the brain has been widely reported [5,6],
and therefore, we did not measure drug concentrations in
the mouse brains in this study.
Phenytoin (PHT) is an effective antiepileptic drug with a
relatively low cost and is therefore widely used in under-
developed regions of the world. In China, PHT has been
included in the national essential drug system as an
important drug for epilepsy treatment. Ginkgo biloba
extract is mainly used for the treatment of cerebrovascular
disorders but is also used as an adjuvant therapy to improve
brain function in patients with epilepsy.
In this study, we hypothesized that G. biloba extract
would reverse PHT resistance in a mouse model of re-
fractory epilepsy, which would indicate that G. biloba
extract represents a potentially important tool for epi-
lepsy management. Therefore, we sought to simulate the
drug treatment regimen used in patients with epilepsy in
combination with G. biloba extract, to investigate the
effects on seizure severity as well as the expression of
proteins involved in drug resistance, including P-GP and
caspase-3, in pentylenetetrazole (PTZ)-kindled/PHT-
treated mice.Materials and methods
Experimental animals
The adult male Kunming mice (18e25 g) used in this study
were purchased from the SPF Laboratory Animal Center at
the Dalian Medical University, Dalian, China. The laboratory
where the animals were housed was maintained at 20e24C
with 50e65% relative humidity. The animals were allowed
free access to food and drinking water. The animal exper-
imental protocol was approved by the Animal Ethics Com-
mittee of Dalian Medical University.
Reagents and instruments
PTZ was obtained from SigmaeAldrich (St Louis, MO, USA),
G. biloba extract from Heilongjiang Treasured Island Phar-
maceutical (Heilongjiang, China), verapamil from Harvest
Shanghai Pharmaceutical (Shanghai, China), PHT sodium
from Xinning Pharmaceutical (Taipei, Taiwan), and meth-
anol was from Thermo Fisher Scientific (Waltham, MA,
USA). Mouse primary monoclonal antibodies including C219
P-GP (Covance Inc., Princeton, NJ, USA), and b-actin
(Abcam, Cambridge, MA, USA), and C219 secondary anti-
bodies (Rockland Inc., Rockland, Ontario, Canada) were
also used. The caspase-3 immunohistochemical kits (SP
method) and 3,30-diaminobenzidine (DAB) chromogenic
agent were obtained from Beijing Zhongshan Golden Bridge
Biotechnology (Beijing, China). The instruments used
included a gel imaging analysis system (UVP, Upland, CA,
USA), desktop refrigerated centrifuge (Thermo Fisher Sci-
entific, Waltham, MA, USA), gel electrophoresis apparatus
(Jim-x Scientific, Shanghai, China), transfer membrane
electrophoresis apparatus (Jingmai Biological Technology,
Liaoning, China), Leica RM 2145 paraffin slicing machine
(Leica Camera AG, Solms, Germany), Olympus BX51 multi-
function microscope (Olympus Corp., Tokyo, Japan), and an
Agilent Model 1100 high-performance liquid chromatog-
raphy (HPLC) system (Agilent, Santa Clara, CA, USA).
Epilepsy model and PHT treatment
Epilepsy was induced in the mice as previously described
[4,7]. The mice were administered PTZ (40 mg/kg intra-
peritoneal, i.p.) dissolved in 0.9% saline solution for 7 days,
and the seizure level and frequency were recorded within
30 minutes of the injection. The seizure level in the mice
400 C. Zhang et al.was scored as follows: Stage 0, no response; Stage 1,
mouth and facial jerks; Stage 2, nodding or myoclonic body
jerks; Stage 3, forelimb clonus; Stage 4, rearing, falling,
hind limb clonus, and forelimb tonus; and Stage 5, tonic
extension of hind limb, status epilepticus or death or both.
Only animals that showed at least five or three consecutive
Stage 2 or 3 seizures respectively were used in further
experiments.
Next, kindled mice were administered PHT (40 mg/kg,
intragastric) for 14 days to simulate drug treatment in pa-
tients with epilepsy. The seizure level and frequency were
then recorded and only animals that showed at least five or
three consecutive Stage 2 or 4 seizures were selected for
further experiments. A separate group of mice (nZ 6) was
administered saline (i.p.) for 21 days to serve as negative
controls to compare P-GP expression with by using Western
blot analysis.
Grouping and drug administration
Thirty PTZ-kindled/PHT-treated mice with seizures were
randomly divided into three treatment groups: 0.9% saline
(negative control), verapamil (a P-GP reversal agent, posi-
tive control), and G. biloba extract. The mice were
administered PHT for 4 days followed by saline; verapamil
(20 mg/kg i.p.); or G. biloba extract (30 mg/kg i.p.) 30
minutes later, and the seizure level and frequency were
observed after an additional 30 minutes on the final day of
treatment [8]. The primary efficacy variable was desig-
nated as
P
(level  frequency of epileptic seizure attack)
and calculated as follows:
P
(level  frequency of epileptic seizure attack) Z (5 
frequency of level 5 seizures) þ (4  frequency of level 4
seizures) þ (3  frequency of level 3 seizures) þ (2  fre-
quency of level 2 seizures) þ (1  frequency of level 1
seizures)
and the results were compared with the saline control
group.
Western blot analysis
To investigate whether treatment with PHT and the G.
biloba extract prevented the upregulation of P-GP in mice
with epilepsy, they were euthanized 30 minutes after the
final drug injection, and the brains were removed. Pyrolysis
liquid was added based on the brain tissue weight (1 mL/
mg), which was then homogenized and centrifuged for 10
minutes at 4C (38,000g) and the supernatant was analyzed
using Western blotting. The samples were diluted with so-
dium dodecyl sulfate loading buffer (1 mL) and placed in
boiling water for 5 minutes. The proteins in the samples
(10 mL) were separated using sodium dodecyl sulfa-
teepolyacrylamide gel electrophoresis (30 mA for 1.5
hours), transferred to an acetic acid cellulose membrane
(9 V for 40 minutes), and then Ponceau-stained overnight at
37C. The membrane was incubated in the P-GP primary
antibody (1:200 dilution in phosphate-buffered saline, PBS)
overnight at 37C, followed by the secondary antibody
(1:12,000 in PBS) in a water bath for 1.5 hours at 37C, andthen DAB staining was performed. The blots were analyzed
using the Gel-Pro analyzer software (UVP, Upland, CA, USA),
and the Bradford assay was used for quantitative protein
analysis. Incubation with the polyclonal anti-b-actin anti-
body was used to ascertain that the gel lanes were loaded
with equal amounts of protein.
Measurement of phenytoin concentration using
HPLC
The concentrations of phenytoin in the brain homogenates
were measured using HPLC. The drug levels were deter-
mined by adding normal saline to the brain tissue (1 mL/mg)
followed by homogenization, and then 2.5 mL of methanol
was added to 0.3 mL of the homogenate. The resulting
mixture was agitated for 3 minutes, followed by centrifu-
gation for 10 minutes at 20,000g. Next, 150 mL of the su-
pernatant was dried with nitrogen and dissolved in 100 mL
of the HPLC mobile phase in a plastic tube. The resulting
mixture was agitated for 1 minute, centrifuged for 10 mi-
nutes at 45,000g, and then injected into the chromatograph
at a volume of 10 mL. The limit of detection of the HPLC
system for PHT was 0.5 mg/mL and the conditions were as
follows: ODS C18 column (200 mm  4 mm); mobile phase,
methanol:water (60:40 v/v); flow rate, 1.0 mL/min; and UV
detection wavelength, 210 nm.
Immunohistochemistry
To investigate whether the G. biloba extract treatment had
protective effects against epilepsy in mice, we examined
caspase-3 expression immunohistochemically. The brain
tissues from the test mice (n Z 7/group) were fixed in 4%
formalin, embedded in paraffin, and sectioned for histo-
logical examination. Dry tissue sections were deparaffi-
nized by placing them in a dye vat containing
dimethylbenzene for 10 minutes, dehydrated using an
alcohol gradient, and then washed thrice with 0.01M PBS.
Next, the tissue sections were placed in 3% hydrogen
peroxide (H2O2) for 15 minutes at room temperature and
washed thrice with 0.01M PBS. After a 15-minute incubation
in sheep serum at room temperature, the caspase-3 rabbit
anti-rat antibody was added to the tissue sample (1:50,
4C, 18 hours), which was stabilized at room temperature
for 30 minutes, and then washed thrice with 0.01M PBS. The
sections were then incubated for 20 minutes with the sec-
ondary antibodies and washed thrice with 0.01M PBS. The
brain tissue sections were finally stained with DAB for 2
minutes, washed for 10 minutes in water, counterstained
for 10 seconds with hematoxylin, and washed again for 10
minutes in water. All the tissue sections were viewed under
a microscope, to identify the caspase-3-positive cells and
randomly selected cortical and hippocampal sections were
used to determine the number of positives per 100 cells.
Data analysis
The data were expressed as mean  standard deviation and
the statistical analyses were performed using the SPSS
version 13.0 software (IBM Corporation, Armonk, NY, USA).
Because the seizure severity data were ranked, the
P-glycoprotein overexpression 401differences between groups were determined using the
ManneWhitney U test, while one-way analysis of variance
(ANOVA) and the StudenteNewmaneKeuls test were used
to determine the differences between the groups in all
other experiments. A p value < 0.05 indicated a significant
difference.
Results
Induction of seizures and P-GP expression
After 7 days of PTZ administration, all the animals exhibi-
ted at least five consecutive Stage 2 steady seizures and
were sensitive to sound. The intragastric administration of
PHT (40 mg/kg) for 14 days elevated P-GP expression more
in the PTZ-kindled mice in than it did in the saline-treated
control group (p < 0.01). These results showed that kindling
and PHT treatment upregulated P-GP expression (Figure 1).
Effects of G. biloba and verapamil on seizure
activity during PHT treatment
All the mice that received PHT (n Z 30) survived up to the
conclusion of the study. On Day 4, the severity of seizures inFigure 1. Seizure severity and P-glycoprotein (P-GP) expression
lepsy in adult male Kunming mice. (A) Seizure severity (n Z 30
measured using Western blot (n Z 6).
Table 1 Effect of Ginkgo biloba extract on seizure severity dur
Treatment group Severity of seizuresa for eac
1 2 3 4 5
Saline/phenytoin 39 34 32 33 26
Verapamil/phenytoin 25 28 25 14 25
Ginkgo biloba extract/phenytoin 16 21 34 16 12
a Severity of seizures Z
P
(level  frequency of seizures), level dethe saline-treated group was significantly greater than that
of the verapamil control and G. biloba extract groups was
(UZ 7.5 andUZ 6.5, respectively,pZ 0.001 each, Table 1).
Furthermore, the seizure severity of the verapamil-treated
group treated was greater than that of the G. biloba
extract-treated group was (UZ 24, pZ 0.048).
P-GP expression in mouse brains
The Western blot analysis revealed a band at 170 kDa,
which corresponded to P-GP. After 4 days of PHT treat-
ment, the P-GP expression in the verapamil- and G. biloba
extract-treated groups was lower than that in the saline-
treated group [F(1, 3) Z 171.860, p Z 0.0001]. The mul-
tiple comparison test (least significant difference method)
showed that there was no significant difference in P-GP
expression between the verapamil- and the G. biloba
extract-treated groups (p Z 0.216, Figure 2).
PHT concentration in mouse brain tissue
As shown in Figure 3, the PHT concentrations in the brain
tissue varied significantly among the three treated groups
(FZ 3.737, pZ 0.048). Compared with the saline plus PHTin a pentylenetetrazole (PTZ)/phenytoin (PHT) model of epi-
). (B) P-GP expression in control and PTZ/PHT-treated mice
ing phenytoin treatment (n Z 10).
h mouse (by subject number) Compared with saline/
phenytoin group
6 7 8 9 10 ManneWhitney U p
35 31 22 32 36 d d
15 20 25 15 26 7.5 0.001
8 14 18 14 8 6.5 0.001
termined using Racine grading method.
Figure 2. Effects of Ginkgo biloba extract and verapamil on P-glycoprotein (P-GP) expression in brains of adult male Kunming
mice (n Z 3). Data are expressed as mean  standard deviation, *p > 0.05 compared with verapamil-treated group. **p < 0.01
compared with saline-treated group. (A) Amount of protein expression in different groups. (B) Typical protein bands.
Figure 3. Concentration of phenytoin (PHT) in mouse brains (n Z 6).
402 C. Zhang et al.group, the brain PHT concentrations of the verapamil plus
PHT phenytoin (p Z 0.033) and G. biloba extract plus PHT
(p Z 0.031) groups were significantly increased. However,
the difference in the PHT concentration was not significant
between the verapamil plus PHT and G. biloba extract plus
PHT groups (p Z 0.975, Figure 3).
Caspase-3 expression in mouse brains
Caspase-3 immunoreactivity in the hippocampal and
cortical regions collected from the mice treated with PHT
in combination with saline, verapamil, or G. biloba extract
was observed under a microscope at 400 magnification.
The neurons showed moderate to strong caspase-3 immu-
noreactivity, and the expression level of the G. biloba
extract-treated group was lower than that of the saline-
treated group was in both the cortical and hippocampal
regions [F(1, 3) Z 35.536 and F(1, 3) Z 27.529, respec-
tively, p Z 0.0001 each; Figure 4, Table 2].
Discussion
A previous study by Pilija et al. [9] reported that G. biloba
increased epilepsy-induced neuronal discharge in an animalmodel. Furthermore, there are a number of case reports of
suspected adverse herb-drug interactions betweenG. biloba
extract and antiepileptic medications [10,11]. Some studies
have investigated convulsions of the intestinal canal of rab-
bits in vitro in this context while others have focused on
human autopsy and case reports. In some reports, the whole
G. biloba plant was administered rather than the plant
extract; however, there are relatively few studies in this
area. Because the results of studies ofG. biloba extract as an
adjuvant treatment for epilepsy are inconsistent, additional
research studies are still required. Our results may be more
acceptable than some previously published data because we
used an experimental mouse model and a stringent experi-
mental design. Themeasures thatwe incorporated are highly
likely to render our results more extrapolatable to humans.
Following treatment with verapamil or G. biloba, the
concentration of PHT sodium increased in the brain tissue
of the treated mice while the P-GP expression level was
relatively low. Therefore, it is highly likely that these two
phenomena are related. Furthermore, these results suggest
that the reversal of antiepileptic drug-resistance at the
protein level may be attributable to an increase in drug
concentrations in target brain tissues.
In this study, we investigated whether the administra-
tion of G. biloba extract in combination with PHT would
Figure 4. Effect of Ginkgo biloba extract on caspase-3 expression in cortex and hippocampus of adult male Kunming mice
(n Z 7). Tan granules represent caspase-3-positive cells.
Table 2 Effect of Ginkgo biloba extract on caspase-3
expression.
Group Number of positive cells/100
nucleated cellsa
Cortical regions Hippocampus
Saline-treated group 74.05  10.46 79.36  10.66
Verapamil control group 63.38  8.66* 68.39  9.50*
Ginkgo biloba extract
group
52.95  3.59*,** 59.19  5.54*,**
*p < 0.01, compared with the saline-treated group.
**p < 0.05, compared with the verapamil-treated group.
a Cortical region: F Z 35.536, p Z 0.0001; hippocampus:
FZ 27.529, pZ 0.0001. Multiple comparisons (least significant
difference method) from analysis of variance.
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mice. The results showed that co-administration of G.
biloba extract and PHT decreased P-GP levels in the cere-
bral cortex and hippocampus, which was accompanied by a
significant decrease in the severity of seizures. Over-
expression of P-GP in the brain may contribute to refractory
epilepsy, and has been associated with the incidence of
seizures [12]. The onset of epilepsy itself may increase P-
GP expression and the brain tissue from patients with epi-
lepsy showed elevated expression levels. In addition,
another study showed that numerous antiepileptic drugs
are P-GP substrates [13].
In the present study, G. biloba extract showed a greater
effect on seizure severity than verapamil did, but P-GP and
caspase-3 expression levels were nearly identical between
the treated groups. This finding implies that G. biloba
extract may influence resistance to epilepsy drugs via
mechanisms other than alteration of P-GP expression. Pre-
vious studies have demonstrated that P-GP is not the only
protein involved in drug efflux from the brain and drugresistance [6,13]. Several proteins have in fact been impli-
cated in the development of drug resistance, including
multidrug resistance-associated protein and lung resistance-
related protein. However, P-GP is the most important
mediator of drug-resistance related efflux of drugs from the
brain. The results of this study demonstrate that inhibition
of P-GP increases the concentration of PHT in the brain,
confirming that P-GP is critically involved in drug efflux and
resistance.
An increase in brain P-GP expression caused by either
illness or epileptic drug treatment in animals with epilepsy
may further interfere with the action of other antiepileptic
drugs that are P-GP substrates. The excessive expression of
P-GP could pump antiepileptic drugs back into the periph-
eral circulation. This recirculation may reduce the brain
concentration of drugs, resulting in drug-resistant re-
fractory epilepsy and the failure of antiepileptic drugs to
induce therapeutic effects. The current study revealed that
G. biloba is a potentially efficacious and well-tolerated
adjunctive treatment for epilepsy in combination with PHT.
The attempts to address the problem of refractory
epilepsy by several researchers revealed that the
cyclooxygenase-2 inhibitor cyclosporine inhibited P-GP,
which increased the concentration of antiepileptic drugs in
the brain and inhibited seizures. Cyclosporine is an immu-
nosuppressant that has not previously found a role in the
treatment of epilepsy. Cyclooxygenase-2 inhibitors may
cause adverse cardiovascular events, but previous studies
have demonstrated the potential of P-GP inhibitors in re-
fractory epilepsy [14]. In this study, it was concluded that G.
biloba extract significantly reduced the expression of P-GP in
the brains of mice with drug-resistant epilepsy. However,
further studies are required to determine whether G. biloba
extract can play an important role as an adjuvant treatment
in epilepsy. These results are in agreement with those of
previous studies, which showed the overexpression of P-GP
was in the brain tissue from patients with epilepsy. Further-
more, it supports the proposition that the overexpression of
404 C. Zhang et al.P-GP in the brains of patients with epilepsy induces drug
resistance.
P-GP is regarded as a second barrier to the entry of
substances into the brain [12] and an increase in its
expression increases the efflux of harmful substances
through the bloodebrainebarrier. However, the adminis-
tration of P-GP inhibitors interferes with this protective
mechanism. Although G. biloba extract appears to show a
favorable profile in experimental animal models, additional
studies are necessary to confirm these findings and to
elucidate the mechanisms mediating its interference with
P-GP expression.
Apoptosis is a complex biological process involving many
cell signaling pathways. Caspase-3 is a critical apoptosis
mediator [15] and, therefore, we measured its expression
to examine the protective effects of this extract on the
brain tissue. Our results showed that G. biloba extract
significantly reduced caspase-3 expression in the brains of
epileptic mice and, therefore, might play a protective role
in the brain during epilepsy treatment. Further confirma-
tion of this protective effect would provide significant
positive evidence for its potential use as a clinical
treatment.
This study demonstrated that the coadministration of G.
biloba extract in mice with PHT decreased P-GP expression
in the brain and enhanced the anticonvulsive effects of
PHT. The results suggest that the overexpression of P-GP in
the brains of PHT-treated mice contributes to the pathology
of refractory epilepsy. Finally, our study suggests that a
novel therapeutic strategy using G. biloba as an adjuvant
treatment could be effective in patients with drug-resistant
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